POSTERS ASCO 2024

Cáncer de mama

Local, regional y adyuvante

Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.

Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.

Abstract: 586 Poster Bd #: 178

Poster

Descargar

Autor
José Manuel Pérez García, MD, PhD

International Breast Cancer Center (IBCC)

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON